AXIOS January 3, 2025
The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab.
Why it matters: The data, which shows double-digit growth in 23 states, offers a snapshot of the sustained growth in demand across the U.S. for the drugs hailed as game-changers in the fight against obesity.
By the numbers: Rhode Island (67.8%), Massachusetts (48%) and New Jersey (35.8%) saw the largest year-over-year growth in prescriptions dispensed between 2023 and 2024.
- There were declines in six states including Arkansas, Louisiana, West Virginia, Idaho, South Dakota and Vermont.
Between the lines: The most prescriptions went to adults ages 55 to 65 (29%), followed by seniors 65...
Today's Sponsors
Today's Sponsor